Summary
Amgen Inc. reported strong financial performance for the fiscal year ended December 31, 2014, with total revenues reaching $20.06 billion, a 7% increase year-over-year. This growth was primarily driven by robust product sales, particularly in international markets, and the inclusion of Kyprolis® sales following the Onyx acquisition. The company demonstrated a commitment to returning capital to shareholders through increased dividends and ongoing stock repurchase programs. Significant pipeline advancements were made in 2014, with several key product candidates progressing through late-stage clinical trials and regulatory submissions. Notably, Repatha™ (evolocumab) for high cholesterol and BLINCYTO™ for acute lymphoblastic leukemia showed promising developments, with BLINCYTO™ receiving FDA accelerated approval in December 2014. Amgen is also strategically investing in next-generation biomanufacturing and has initiated a restructuring plan to optimize its cost structure and reallocate resources towards innovation and new product launches. However, the company faces increasing competition from biosimilars and anticipates patent expirations for key products, which will require continued focus on R&D and strategic pipeline management.
Financial Highlights
55 data points| Revenue | $20.06B |
| Cost of Revenue | $4.42B |
| Gross Profit | $15.64B |
| SG&A Expenses | $4.70B |
| Operating Expenses | $13.87B |
| Operating Income | $6.19B |
| Interest Expense | $1.07B |
| Net Income | $5.16B |
| EPS (Basic) | $6.80 |
| EPS (Diluted) | $6.70 |
| Shares Outstanding (Basic) | 759.00M |
| Shares Outstanding (Diluted) | 770.00M |
Key Highlights
- 1Total revenues increased by 7% to $20.06 billion in 2014, driven by a 6% rise in total product sales.
- 2Product sales in the Rest of World (ROW) grew by 11%, outpacing the 5% growth in U.S. product sales.
- 3Significant pipeline progress includes regulatory submissions and positive Phase 3 data for Repatha™ (evolocumab) and FDA accelerated approval for BLINCYTO™ (blinatumomab).
- 4Amgen initiated a restructuring plan involving staff reductions and facility consolidations, expected to result in significant pre-tax charges but aimed at improving cost structure and reinvesting in innovation.
- 5The company continued to return capital to shareholders with a 30% increase in quarterly dividends and active stock repurchases.
- 6Key products like XGEVA® and Prolia® demonstrated strong double-digit growth (20% and 38% respectively).
- 7Amgen is expanding its biosimilar development program, planning to add three more biosimilar molecules to its portfolio, bringing the total to nine.